From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Stephen Ansell, MD, PhD, of Mayo Clinic, Rochester, MN, discusses ways in which measuring measurable residual disease (MRD) may be useful. One way in which using MRD may be advantageous is when early intervention for a disease such as diffuse large B-cell lymphoma, is needed, and data is required to differentiate which patients are not cured and who are at risk of relapse. Prof. Ansell reports on findings from clinical trials using MRD to enable earlier intervention for lymphoma, and expresses hope for the future development of tools to improve management of these patients.
MRD in lymphoma
